Article Figures & Data
Figures
- FIGURE 1.
Incomplete manual tumor segmentations compared with predicted segmentations on maximum-intensity projections of PSMA PET scans of 6 patients with prostate cancer.
- FIGURE 2.
Predicted segmentations on maximum-intensity projections of 18F-FDG PET scans of lung cancer, melanoma, lymphoma, head and neck cancer (H & N), and breast cancer. Pre- and posttherapy scans of breast cancer are shown (bottom row), with first 2 patients from left to right having pCR and the others being nonresponders.
- FIGURE 3.
(A and B) Lesionwise (A) and voxelwise (B) analysis of tumor detection and segmentation. (C and D) Prostate cancer detection rates by DeepSSTL approach throughout different stages of training progression (C) and compared with baseline models (D). DSC = Dice similarity coefficient; FDR = false-discovery rate; NPV = negative predictive value; PPV = positive predictive value; TNR = true-negative rate; TPR = true-positive rate.
- FIGURE 4.
(A and B) Receiver-operating-characteristic curves for radiomics classifier (A) and risk model (B) for prostate cancer. (C and D) Box plots of predicted risk scores vs. overall PSMA-RADS scores (C) and post-PSMA PET therapies (D).
- FIGURE 5.
Predicted segmentations on maximum-intensity projections of PSMA PET scans of prostate cancer from datasets 1 (top row) and 2 (bottom row). MTV, PSA doubling times (DT), and follow-up PSA levels were measured in cubic centimeters, months, and ng/mL, respectively.
- FIGURE 6.
(A) Forest plots of univariable and multivariable Cox regression analysis. (B) Kaplan–Meier survival curves for head and neck cancer. (C) Imaging measures quantified from pre- and posttherapy scans of breast cancer.
Tables
Characteristic Data Characteristic Data Dataset 1* Dataset 3† Age (y) (mean ± SD) 65.67 ± 7.97 Age (y) (mean ± SD) 60.11 ± 16.51 Sex Sex Men 270 Men 290 Women 0 Women 211 Overall PSMA-RADS score Dataset 4‡ NA 12 Age (y) (mean ± SD) 62.47 ± 7.78 1 3 Sex 2 24 Men 62 3 63 Women 12 4 48 AJCC stage 5 120 I 14 Dataset 2* II 5 Age (y) (mean ± SD) 66.46 ± 7.35 III 13 Sex IV 42 Men 138 Surgery Women 0 No 70 Gleason score Yes 4 NA 2 Chemotherapy ≤6 11 No 61 7 43 Yes 13 8 29 Radiotherapy time (d) 37 (31–47) 9 44 Dataset 5§ 10 9 Age (y) (mean ± SD) 48.69 ± 10.33 Initial PSA level (ng/mL) 6.38 (0.02–5,000.00) Sex Follow-up PSA level (ng/mL) 2.24 (0.00–7,270.00) Men 0 PSA doubling time (mo) 5.20 (0.23–81.70) Women 36 Post-PSMA PET therapy Pathologic response NA 37 pCR 10 None 7 Non-pCR 26 Local 18 Systemic androgen-targeted 56 Systemic and cytotoxic 20 Univariable Cox regression Multivariable Cox regression Parameter Hazard ratio 95% CI P Hazard ratio 95% CI P C index MTV 1.01 1.01–1.02 <0.001 0.99 0.97–1.02 0.57 0.68 TLA 1.00 1.00–1.00 <0.001 1.00 1.00–1.00 0.27 0.69 Lesion no. 1.38 1.13–1.69 0.002 0.84 0.53–1.34 0.47 0.69 SUVmean 1.11 1.04–1.18 0.002 0.74 0.53–1.03 0.07 0.65 SUVmax 1.04 1.02–1.06 <0.001 1.06 0.96–1.17 0.27 0.65 Age 1.06 1.01–1.10 0.02 1.08 1.02–1.14 0.01 0.61 Sex 1.27 0.49–3.28 0.62 1.56 0.52–4.67 0.43 0.47 Surgery 1.48 0.45–4.83 0.52 0.71 0.18–2.76 0.62 0.50 Chemotherapy 0.57 0.20–1.61 0.29 0.67 0.12–3.95 0.66 0.47 Radiotherapy time 0.95 0.88–1.03 0.23 0.94 0.82–1.08 0.38 0.46 AJCC stage 1.62 1.12–2.34 0.01 1.05 0.57–1.92 0.88 0.61 Risk score 1.27 1.11–1.45 <0.001 1.69 1.07–2.66 0.02 0.71 Model and parameter Accuracy AUC Area under precision-recall curve True-positive rate Positive predictive value True-negative rate Negative predictive value MTV 0.42 0.55 0.28 1.00 0.32 0.19 1.00 TLA 0.67 0.58 0.30 0.50 0.42 0.73 0.79 Lesion no. 0.47 0.67 0.39 0.80 0.32 0.35 0.82 SUVmean 0.72 0.44 0.28 0.30 0.50 0.88 0.77 SUVmax 0.64 0.44 0.27 0.40 0.36 0.73 0.76 Decision tree 1 0.72 0.72 0.51 0.50 0.50 0.81 0.81 Decision tree 2 0.84 0.76 0.67 0.43 1.00 1.00 0.82
Supplemental Data
Files in this Data Supplement:
